论文部分内容阅读
血管内皮生长因子(VECF),又称为血管通透因子(VPF)。已有研究证实,VEGF作为最关键的血管形成因子在实体肿瘤的生长、转移过程中发挥重要的调节作用。近年来关于VEGF与恶性血液病发生、发展、预后的关系正逐渐受到人们重视。本文通过对急性非淋巴细胞白血病(AML)患者治疗前后血浆VEGF水平及骨髓上清液中VEGF水平的检测,以期探索VEGF与白血病的发生及预后的关系。1资料与方法1.1研究对象32例急性非淋巴细胞白血病患者均为初诊未治的病例,其诊断标准参照张之南。血液病及疗效标准(第2版)。对以上患者均进行正规治疗并随访其预后情况,其中化疗1个疗程即达到完全缓解并在以后的治疗中持续
Vascular endothelial growth factor (VECF), also known as vascular permeability factor (VPF). Studies have shown that VEGF plays an important regulatory role in the growth and metastasis of solid tumors as the most important angiogenic factor. In recent years, the relationship between VEGF and the occurrence, development and prognosis of hematologic malignancies is gradually receiving attention. The aim of this study was to investigate the relationship between VEGF and leukemia and the prognosis of acute non-lymphocytic leukemia (AML) patients before and after treatment of plasma VEGF levels and bone marrow supernatant VEGF levels. 1 Materials and Methods 1.1 Study Subject 32 cases of patients with acute non-lymphocytic leukemia are newly diagnosed cases, the diagnostic criteria refer to Zhang Zhinan. Hematopathy and efficacy standards (2nd edition). The above patients were regular treatment and follow-up of their prognosis, of which a course of chemotherapy to achieve complete remission and continued treatment in the future